Back to Newsroom

U.S. FDA approves Celltrion's AVTOZMA® (tocilizumab-anoh), a biosimilar to ACTEMRA®


- The intravenous (IV) formulation of AVTOZMA® (tocilizumab-anoh) is expected to be available in the U.S. in August 2025

- Approval was received for multiple indications, including rheumatoid arthritis (RA), giant cell arteritis (GCA),   polyarticular juvenile  idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA) and COVID-19[1]

- AVTOZMA® becomes Celltrion's fifth immunology biologic and seventh biosimilar approved by the FDA


JERSEY CITY, N.J., Jan. 30, 2025 -- Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a biosimilar to ACTEMRA®. AVTOZMA is indicated for the treatment of multiple diseases including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA) and coronavirus disease (COVID-19).[1]

 

"Introducing both IV and SC
formulations of AVTOZMA provides flexibility and a wider range of treatment
options," said Thomas Nusbickel, Chief Commercial Officer at Celltrion
USA. "This approval represents a strategic addition to our immunology
portfolio, further strengthening our commitment to delivering accessible and
high-quality treatment options for patients and healthcare providers. Our goal
is to provide safe and effective alternatives and ensure appropriate access so
plan sponsors can address unique population needs."

 

The FDA's decision is based on a
comprehensive data package and the totality of evidence, including the results
from a phase III study demonstrating biosimilarity between AVTOZMA and
reference tocilizumab in patients with moderate to severe active RA. The primary
endpoint was met in terms of change from baseline in disease activity score
using 28 joints (DAS28)-ESR at Week 24, and the final 1-year results supported
comparability in secondary efficacy, pharmacokinetic (PK), safety and
immunogenicity results between AVTOZMA and reference tocilizumab. The clinical
results demonstrated that AVTOZMA and its reference tocilizumab are highly
similar and have no clinically meaningful differences in terms of efficacy,
safety, pharmacokinetics (PK) and immunogenicity.[2]

 

In accordance with the patent settlement
agreement with Genentech, the intravenous (IV) formulation of AVTOZMA® (tocilizumab-anoh)
is expected to be available in the U.S. in August 2025. Celltrion has a license
to market the subcutaneous formulation in the U.S. commencing on the license
date, which remains confidential.

 

AVTOZMA is Celltrion's seventh biosimilar
granted marketing authorization in the U.S.

 

About AVTOZMA® (tocilizumab-anoh)[1] 

AVTOZMA® (tocilizumab-anoh), containing the active ingredient tocilizumab, is a recombinant humanized monoclonal antibody that acts as an interleukin 6 (IL-6) receptor antagonist. Based on data from the global Phase III clinical trial designed to evaluate the efficacy, pharmacokinetics (PK), safety, and immunogenicity of CT-P47 compared to reference tocilizumab, AVTOZMA was filed for regulatory approval with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) in January and February 2024, respectively.  

 

INDICATION 

AVTOZMA® (tocilizumab-anoh)
is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of:

- Rheumatoid Arthritis (RA): Adult patients with moderately to severely active RA who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

- Giant Cell Arteritis (GCA): Adult patients with GCA.

- Polyarticular Juvenile Idiopathic Arthritis (pJIA): Patients 2+ years-old with active pJIA.

- Systemic Juvenile Idiopathic Arthritis (sJIA): Patients 2+ years-old with active sJIA.

- COVID-19: Hospitalized adult patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

 

IMPORTANT SAFETY INFORMATION

 

WARNING: RISK OF SERIOUS INFECTIONS

 

AVTOZMA® and other
tocilizumab products may increase the risk of serious infections, potentially
leading to hospitalization or death, especially in patients using concurrent
immunosuppressants.

 

If a serious infection develops, interrupt AVTOZMA until
the infection is controlled. Reported infections include:

- Active tuberculosis (TB) which may present with pulmonary or extrapulmonary disease. Test for latent TB before and during treatment (except in COVID-19 patients) and treat latent infections before starting AVTOZMA.

- Invasive fungal infections: Such as candidiasis, aspergillosis, and pneumocystis, may present as disseminated rather than localized disease.

- Opportunistic infections, including bacterial, viral and other opportunistic pathogens.

 

Monitor patients for signs of infection, including TB,
during and after AVTOZMA treatment.


Contraindications: Known hypersensitivity to tocilizumab products.


Serious Infections. Serious and sometimes fatal infections have been reported with AVTOZMA. Do not use during active infections, including localized infections. Discontinue AVTOZMA if a serious infection occurs and resume only once controlled. 

Gastrointestinal (GI) Perforation. Gastrointestinal perforations, often linked to diverticulitis, have been reported with tocilizumab. Use AVTOZMA cautiously in high-risk patients and promptly evaluate new abdominal symptoms for early detection and management.

Hepatoxicity. Monitor for hepatic injury signs. Avoid AVTOZMA if ALT/ AST >1.5x ULN (RA/GCA) or >10x ULN (COVID-19); discontinue if ALT/AST >5x ULN or symptoms of liver disease develop.

Changes in Laboratory Parameters. Monitor neutrophils, platelets, liver enzymes, and lipids due to potential treatment-related changes; avoid initiating AVTOZMA in patients with critically low ANC or platelet counts.

Immunosuppression. The impact of AVTOZMA on malignancy development is unknown, but it may increase risk as an immunosuppressant.

Hypersensitivity Reactions, including anaphylaxis, and death, have occurred; administer IV infusions with anaphylaxis management support, discontinue permanently if reactions occur, and avoid use in patients with known hypersensitivity.

Demyelinating Disorders. The impact of tocilizumab on demyelinating disorders is unknown, but rare cases were reported; monitor symptoms and use caution with preexisting or recent disorders.

Active Hepatic Disease and Hepatic Impairment. Treatment with AVTOZMA is not recommended.

Live Vaccines. Avoid concurrent use with AVTOZMA

Adverse Reactions (≥5%) include upper respiratory tract infections, nasopharyngitis, headache, hypertension, elevated ALT, and injection site reactions.

For more information, see Full Prescribing
Information
.

 

About Celltrion

Celltrion is a leading biopharmaceutical company based in Incheon, South Korea that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. Celltrion endeavors to offer high-quality, cost-effective solutions through an extensive global network that spans more than 110 countries. Celltrion has seven biosimilars approved by the U.S. FDA: INFLECTRA® (infliximab-dyyb), TRUXIMA® (rituximab-abbs), HERZUMA® (trastuzumab-pkrb), VEGZELMA® (bevacizumab-adcd), YUFLYMA®(adalimumab-aaty), STEQEYMA® (ustekinumab-stba), and AVTOZMA® (tocilizumab-anoh), as well as novel biologic ZYMFENTRA® (infliximab-dyyb). For more information, please visit https://www.celltrion.com/en-us.

 

FORWARD-LOOKING STATEMENT

Certain information set forth in this
press release contains statements related to our future business and financial
performance and future events or developments involving Celltrion Inc. and its
subsidiaries that may constitute forward-looking statements, under pertinent
securities laws. This press release contains forward looking statements. These
statements may be also identified by words such as "prepares,"
"hopes to," "upcoming," "plans to," "aims
to," "to be launched," "is preparing," "once
gained," "could," "with the aim of," "may,"
"once identified," "will," "working towards,"
"is due," "become available," "has potential to,"
the negative of these words or such other variations thereon or comparable
terminology.

In addition, our representatives may make
oral forward-looking statements. Such statements are based on the current
expectations and certain assumptions of Celltrion Inc. and its subsidiaries'
management, of which many are beyond its control.

Forward-looking statements are provided to
allow potential investors the opportunity to understand management's beliefs
and opinions in respect of the future so that they may use such beliefs and
opinions as one factor in evaluating an investment. These statements are not
guarantees of future performance and undue reliance should not be placed on
them.

Such forward-looking statements
necessarily involve known and unknown risks and uncertainties associated with
the company's business, including the risk factors disclosed in its Annual
Report and/or Quarterly Reports, which may cause actual performance and
financial results in future periods to differ materially from any projections
of future performance or results expressed or implied by such statements.

Celltrion Inc. and its subsidiaries
undertake no obligation to update forward-looking statements if circumstances
or management's estimates or opinions should change except as required by
applicable securities laws.

 

Trademarks

AVTOZMA® is
a registered trademark of Celltrion Inc.
ACTEMRA® is a registered trademark of Chugai
Pharmaceutical Co., Ltd. 

 

References

[1] AVTOZMA U.S. prescribing
information (2024)
[2] Gerd Burmester et al., Similar Efficacy, PK, Safety, and
Immunogenicity of Tocilizumab Biosimilar (CT-P47) and Reference Tocilizumab in
Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Week 52 Results
from the Phase III Single Transition Study. Poster Presentation (abstract no.
0502). Presented at ACR 2024. Available at: https://acrabstracts.org/abstract/similar-efficacy-pk-safety-and-immunogenicity-of-tocilizumab-biosimilar-ct-p47-and-reference-tocilizumab-in-patients-with-moderate-to-severe-active-rheumatoid-arthritis-week-52-results-from-the/ [Last
accessed December 2024]